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Background: Alzheimer’s disease (AD) pathology and hypertension (HTN) are risk factors for
development of white matter (WM) alterations and might be independently associated with these
alterations in older adults.
Objective: To evaluate the independent and synergistic effects of HTN and AD pathology on
WM alterations.
Methods: Clinical measures of CVD risk were collected from 62 participants in University of
Kentucky Alzheimer’s Disease Center studies who also had CSF sampling and MRI brain scans.
CSF Aβ1–42 levels were measured as a marker of AD, and fluid-attenuated inversion recovery
imaging and diffusion tensor imaging were obtained to assess WM macro and microstructural
properties. Linear regression analyses were used to assess the relationships among WM
alterations, CVD risk and AD pathology. Voxelwise analyses were performed to examine spatial
patterns of WM alteration associated with each pathology.

Author Manuscript

Results: HTN and CSF Aβ1–42 levels were each associated with white matter hyper-intensities
(WMH). Also, CSF Aβ1–42 levels were associated with alterations in normal appearing white
matter fractional anisotropy (NAWM-FA), whereas HTN was marginally associated with
alterations in NAWM-FA. Linear regression analyses demonstrated significant main effects of
HTN and CSF Aβ1–42 on WMH volume, but no significant HTN × CSF Aβ1–42 interaction.
Furthermore, voxelwise analyses showed unique patterns of WM alteration. associated with
hypertension and CSF Aβ1–42.
Conclusion: Associations of HTN and lower CSF Aβ1–42 with WM alteration were statistically
and spatially distinct, suggesting independent rather than synergistic effects. Considering such
spatial distributions may improve diagnostic accuracy to address each underlying pathology.

Author Manuscript
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1.

Introduction

Author Manuscript

Over 50% of individuals who develop dementia have mixed pathologies at autopsy.[1–3]
The two most prevalent contributors to mixed pathology are Alzheimer’s disease (AD) and
cerebrovascular disease (CVD), and intense efforts are being made to develop in vivo tests
for early diagnosis.[1, 3] Antemortem identification of AD pathology has become easier
since the development of in vivo markers of amyloid and tau using cerebrospinal fluid (CSF)
or positron emission tomography (PET) scans.[4–7] Accurate identification and
classification of CVD in vivo, however, remains challenging. Markers of CVD include areas
of hyper-intense signal in white matter (white matter hyper-intensities, WMH) on T2weighted MRI of the brain, and more recently, alterations in microstructural properties of
WM such as fractional anisotropy (FA) detected using diffusion tensor imaging (DTI).[8–
10]
WMH also occur in the pre-dementia stage of familial AD, including in those with no
appreciable CVD risks.[11, 12] It remains unclear whether these WM alterations should be
attributed to AD, CVD, or both pathological processes. Further, it is unknown whether the
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effects of AD and CVD are independent or synergistic. The present study examined
relationships between CSF beta-amyloid (Aβ1–42) and CVD risk factors with both WMH
volumes and FA values within regions of normal appearing WM. The central analysis of the
study utilized multiple linear regression to determine whether AD pathology and CVD risk
are independently or synergistically associated with WM alterations. An interaction term
was used to explore potential synergistic effects, while main effects explored potential
independent effects of AD pathology and CVD risk. Voxelwise analyses were then used to
determine the spatial distribution of WMH changes associated with CSF Aβ1–42 levels
and/or CVD risk factors.

2.
2.1.

Methods
Participants:

Author Manuscript

Participants enrolled in the University of Kentucky Alzheimer’s Disease Center (UK-ADC)
cohort and affiliated clinical trials were included in the present study. All studies used
identical imaging and cerebrospinal fluid collection protocols, and all research protocols
were approved by the University of Kentucky Institutional Review Board. All participants
gave written informed consent.

Author Manuscript

Inclusion criteria for the current study included a classification of cognitively normal (CN)
or mild cognitive impairment (MCI), which was based on Clinical Dementia Rating (CDR)
[13] global scores: CN (CDR = 0) and MCI (CDR = 0.5). Additionally, all participants were
required to have MRI data that met quality control standards for motion and artifacts,
available CSF Aβ1–42 data, and clinical data regarding current or previous diagnosis of
hypertension (HTN: 1=yes, 0=no), hyperlipidemia (HLD: 1=yes, 0=no), and diabetes
mellitus (DM: 1=yes, 0=no). In addition, data on antihypertensive medication use, history of
cardiovascular disease, atrial fibrillation, cigarette smoking, blood pressure, and lipid levels
were used to calculate a modified Framingham 10-year Stroke Risk Score (mFRS) for each
participant (FRS was modified because data on left ventricular hypertrophy were not
available).[14]
2.2.

MRI Protocol and Analysis:

Author Manuscript

Data were collected on a Siemens 3 Tesla TIM TRIO scanner using a 32-channel head coil
at the University of Kentucky Magnetic Resonance Imaging and Spectroscopy Center. Two
high-resolution 3D T1-weighted images were obtained using a magnetization-prepared rapid
acquisition gradient echo (MP-RAGE) sequence [repetition time (TR) = 2530 ms, inversion
time (TI) = 1100 ms, echo time (TE) = 2.56 ms, Flip angle = 7 degrees, 1 mm isotropic
voxels]. Fluid-attenuated inversion recovery (FLAIR) images were acquired using a 3D
sequence [TR = 6000ms, TI = 2200ms, TE = 338ms, 1mm isotropic voxels]. DTI used an
axial, double-refocused spin-echo, echo planar imaging sequence [TR = 8000ms, TE =
96ms, FOV = 224mm2, 52 contiguous slices, 2mm isotropic voxels] with 60 non-collinear
encoding directions (b = 1000 s/mm2) and 8 images without diffusion weighting (b0, b = 0
s/mm2).
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2.2.1. FLAIR Sequence Analysis and WMH Mask Generation: FLAIR image
processing was performed using a previously described protocol.[15] Briefly, MP-RAGE
and FLAIR images were radiofrequency inhomogeneity-corrected using the N3-correction
algorithm provided in MIPAV (http://mipav.cit.nih.gov). The two MP-RAGE images were
registered to each other using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12)
and then averaged. The averaged MP-RAGE image was then registered to FLAIR image
using SPM12. Next, the FSL (v5.0.9) brain extraction tool[16] was used to remove nonbrain tissue from the average MP-RAGE image to create a binary mask of brain tissue. This
mask was then applied to the FLAIR image to remove non-brain tissue. Multimodal
segmentation was performed with SPM12 using the average MP-RAGE and FLAIR image.
The brain was segmented into gray matter, two separate white matter segments, CSF, and
other tissues segments using a previously validated segmentation method.[17] The two WM
segments were combined to form a single WM mask, which was dilated and then multiplied
with the FLAIR image to form a FLAIR WM mask. Matlab 2015b was then used to
determine the mean and standard deviation (SD) of the FLAIR WM in each participant by
fitting a Gaussian model curve to the histogram of WM voxels intensity. The FLAIR WM
images were then thresholded at 3 SDs above each participant’s mean value to identify areas
of WMH in that participant. The resulting WMH mask were then manually edited to remove
artifacts around the interventricular septum and inferior slices.[17] The summed volume of
remaining voxels in each participant was used as a measure of WMH volume.

Author Manuscript

2.2.2. DTI Sequence Analysis: The goal of the DTI analyses was to compute mean FA
values within regions of normal-appearing WM (NAWM) in each participant’s FLAIR
image. DTI image processing was performed using a previously described protocol.[18]
Briefly, FSL (v5.0.9) was used to perform pre-processing for motion and eddy-current
correction with outlier detection and replacement.[19, 20] Following brain extraction, the
FMRIB Diffusion Toolbox (FDT v3.0) was used to fit a voxelwise diffusion tensor model,
determine the eigenvalues, and calculate FA.[21] FA images were registered into FMRIB FA
1mm space, averaged to form a mean FA image to then generate a common WM skeleton,
and finally project each participants FA image onto the group skeleton using tract-based
spatial statistics (TBSS).[21]

Author Manuscript

The same registration parameters were then used to project the FA image to standard
(MNI152 T1 1mm3) space. The common track skeleton was used together with the WMH
images in the TBSS non-FA pipeline.[21] These WMH images were then subtracted from
the TBSS skeleton in order to create a NAWM image for each participant that comprised
only WM outside of WMH. The mean global FA was then extracted from each participant’s
NAWM image using fslstats FSL statistical tool.
2.2.3. Cerebral Microbleed Analysis: Measures of cerebral microbleeds (CMBs)
were collected from 62 participants who had CSF sampling. Gradient recalled echo (GRE)
MRI sequence was obtained to assess CMBs. CMBs were visually rated using Microbleeds
Anatomical Rating Scale (MARS). [22]
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CSF collection and analysis was performed as previously described.[23] In brief,
participants underwent lumbar puncture the same day as MRI scanning. CSF was collected
in the morning after fasting since midnight and stored in a − 80 °C freezer prior to shipment
on dry ice to the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Biomarker Core
laboratory at the University of Pennsylvania Medical Center. CSF levels of Aβ1–42 were
measured using the multiplex xMAP Luminex Platform (Luminex Corp, Austin, TX) with
Innogenetics (INNO-BIA, AlzBio3; Ghent, Belgium) immunoassay kit as previously
described.[24]
2.4.

Statistical Analysis:

Author Manuscript

2.4.1. Statistical Analyses: Independent samples t-tests and chi-square tests were used
to assess differences between CN and MCI groups in demographic and clinical measures,
CSF Aβ1–42, and measures of WM alteration. Bivariate relationships between CSF Aβ1–42,
mFRS, HTN status, HLD status, DM status, smoking status and quantitative measures of
WMH volume and DTI-based FA measures were investigated using partial correlations
controlling for age and sex.

Author Manuscript

As HTN was the only CVD risk factors associated with WMH volume, HTN was used as a
marker of CVD risk in further analyses. Next, separate linear regression models were used to
explore the association of HTN and CSF Aβ1–42 with WMH volume and NAWM-FA. Each
model included main effects of HTN and CSF Aβ1–42, a HTN × CSF Aβ1–42 interaction,
and age, sex, and cognitive status as covariates. The interaction term was included to explore
any synergistic effects of HTN and CSF Aβ1–42 on WM alterations. If the interaction term
was not significant, it was removed from the model and the model was refit to the data in
order to explore the independent effects of HTN and CSF Aβ1–42. Finally, the above models
were repeated with the mFRS included as additional covariate.
In order to assess potential contributions from cerebral amyloid angiopathy (CAA), bivariate
relationships of CSF Aβ1–42 with CMBs in the frontal, parietal, temporal, occipital lobes
and the basal ganglia were investigated using partial correlations controlling for age and sex.
Next, linear regression was performed to explore whether WMH and significant CMBs
predicted CSF Aβ1–42 independently after controlling for age, sex, and cognitive status.
SPSS 23 (IBM, Chicago, IL) was used for all statistical analyses, and significance was set at
0.05.

Author Manuscript

2.4.2. Voxelwise Regression Analysis: FSL’s Randomise tool was used to perform
exploratory voxelwise regression analyses to examine the spatial location of WM alteration
associated with CSF Aβ1–42 and HTN. CSF Aβ1–42 (measured in pg/ml) was treated as a
continuous variable, whereas the clinical diagnosis of HTN, systolic BP >139, or diastolic
BP > 89 were used as criteria indicating presence of HTN. Each analysis included either
CSF Aβ1–42 or HTN as the predictor of interest and age, sex, and education as covariates.
These models were then used to identify voxels where the presence of WMH were
associated with CSF Aβ1–42 or HTN. Correction for multiple comparisons across all voxels
was performed using the false-discovery rate (FDR) tool provided with FSL (https://
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fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDR), which uses the distribution of p-values from every voxel
in order to determine an appropriate threshold to reduce false-positives.[25] Results were
then compared to the ICBM-DTI-81 WM labels atlas to identify the tracts that included
significant voxels.

3.

Results:

Author Manuscript

A total of 62 participants met all criteria for inclusion, including 26 CN (CDR=0) and 36
MCI (CDR=0.5). Demographic and clinical features of the participants are presented in
Table 1. The MCI group had higher percentages of participants with HTN and HLD than the
CN group (p < .001). In addition, CSF Aβ1–42 was significantly lower in the MCI group than
the CN group (p = .005). There was no difference between CN and MCI groups in other
clinical measures or in measures of WM alterations. Results of bivariate partial correlations
controlling for age, sex, and cognitive status are shown in Table 2. The mFRS, HLD and DM
were not associated with either WMH volume or FA in NAWM. HTN and lower CSF
Aβ1–42 (which is associated with higher amyloid plaque burden), however, were both
correlated with higher WMH volume (r = 0.30, df = 57, p = 0.021 and r = - 0.30, df = 57, p =
0.021, respectively). CSF Aβ1–42 but not HTN was associated with lower FA in NAWM (r =
0.40, df = 57, p = 0.002 and r = −0.23, df = 57, p = 0.08, respectively).

Author Manuscript

Results of linear regression analysis examining the effects of CSF Aβ1–42, HTN, the CSF
Aβ1–42 × HTN interaction on WMH volume, controlling for age, sex, and cognitive status
are shown in Table 3 (Model 1). Results after removing the non-significant interaction term
are also shown (Model 2). Models 1 and 2 were repeated with the inclusion of mFRS as an
additional covariate (Table 3; Models 3 and 4, respectively). Results of linear regression
analysis examining the effects of CSF Aβ1–42, HTN, the CSF Aβ1–42 × HTN interaction on
NAWM-FA controlling for age, sex, and cognitive status are shown in Table 4 (Model 1).
Results after removing the non-significant interaction term are also shown (Model 2).
Models 1 and 2 were repeated with the inclusion of mFRS as an additional covariate (Table
4; Models 3 and 4, respectively).

Author Manuscript

Results from the voxelwise regression analyses demonstrated both HTN and CSF Aβ1–42
were primarily associated with WMH in different areas, with 95% of HTN-related WMH
voxels and 90% of CSF Aβ1–42 -related WMH voxels being unique (i.e., non-overlapping)
(Figure 1). WMH associated with HTN were primarily located in the right inferior frontooccipital fasciculus, right superior longitudinal fasciculus, and bilateral periventricular WM
along the body of the lateral ventricles. In contrast, WMH associated with CSF Aβ1–42 were
primarily located at the posterior corona radiata bilaterally and periventricular regions near
the anterior horns of the lateral ventricles. The primary area of overlap was in the posterior
portion of the right cingulum (Figure 1).
In order to assess the impact of CMBs on the relationships observed between CSF Aβ1–42
and WM alterations, partial correlations were performed to examine the relationships of
Aβ1–42 with basal ganglia and lobar CMBs (in frontal, parietal, temporal, and occipital lobes
separately). Results of the analyses demonstrated that Aβ1–42 was associated with parietal
CMBs (r = −0.28, p = .037) but not with any other CMBs (p > 0.05). A linear regression
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analysis was then performed to examine whether parietal CMBs and WMH independently
predicted CSF Aβ1–42. Results demonstrated that Aβ1–42 was significantly predicted by
WMH volume (β = −0.32, p =.025) and only marginally predicted by parietal CMBs (β =
−0.25, p = .06) while controlling for age, sex, and cognitive status.

4.

Discussion:

Author Manuscript

Results from this study demonstrate that CSF levels of Aβ1–42 and HTN are each associated
with WM damage, manifesting as both overt areas of WMH and microstructural alterations
in NAWM. Importantly, these processes appear to independently contribute to WM changes
and affect spatially distinct areas of WM. These data demonstrate that pathologies
underlying or caused by CSF Aβ1–42 and HTN exert additive rather than synergistic effects
on WM alteration. Our work also raises the question of whether the nature of white matter
alteration associated with HTN is the same as that associated with CSF Aβ1–42. Since the
spatial distributions of WM changes were distinguishable (HTN vs CSF Aβ1–42), equivalent
underlying mechanisms should not be assumed, despite some similarities in their
appearances on MRI. Assuming that both types of WM alteration are deleterious, it follows
that treatment of mixed disease states may require interventions aimed at both processes to
achieve maximal clinical efficacy.

Author Manuscript

Initial analyses sought to determine whether CVD risk factors and/or CSF Aβ1–42 levels
were associated with WM alteration as assessed by overt WMH or subtler microstructural
changes within NAWM that are not detectable at the macrostructural level. The modified
Framingham CVD risk score was not associated with either marker of WM alteration.
Previous studies examining the relationship between the mFRS and WM alterations have
been equivocal with one study finding a relationship[26] and another failing to find such a
relationship in older adults.[27] These discordant findings may be due to differences in the
cohorts, including clinical, environmental, and cultural characteristics. In addition, the
Framingham CVD risk score is intended to predict future CVD, which may account for the
lack of cross-sectional relationship between mFRS and WM alterations. Of note, a recent
study failed to find a relationship between mFRS and WM but did find that mFRS predicted
future cognitive decline.[27]

Author Manuscript

HTN was associated with both WMH volume and FA in NAWM, which is consistent with
previous reports.[28, 29] The potential mechanisms underlying the association between
HTN and WM alteration are unclear, but several explanations have been proposed. It is
possible that that reduced cerebral blood flow could contribute to transient ischemic injury
or that HTN-induced endothelial damage could result in extravasation of blood products into
WM tissue resulting in injury.[30–32] WMH may represent areas of reduced vascular
integrity,[33] whereas alteration in NAWM may include decreased myelin organization,
lower axonal coherence, or decrease in axonal numbers otherwise related to reduced
vascular integrity.[34]
Lower CSF Aβ1–42 levels were also associated with both higher WMH volume and lower
FA in NAWM. These findings are consistent with previous studies, which found that WMH
volume is higher[11, 12] and FA is lower[35, 36] in AD brain compared to healthy controls.
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The exact mechanism underlying these relationships also remains unclear, but several
possibilities exist. First, we noted that soluble Aβ1–42 oligomers were present in WM and
were associated with loss of axons as well as breakdown in myelin content.[37, 38] Further,
soluble Aβ1–42 is toxic to oligodendrocytes and inhibits formation of new myelin sheaths in
vitro.[39, 40] It is also possible that Aβ1–42 may indirectly influence WM through increased
inflammation,[41] decreased cerebral blood flow secondary to a hypocholinergic state,[42]
or damage to blood vessels secondary to cerebral amyloid angiopathy.[12, 43]

Author Manuscript

The most important finding of the present study is that a history of HTN and CSF Aβ1–42
levels are independently associated with WM alterations and have additive effects. Of note,
AD and HTN often coexist in older adults.[44] However, linear regression analyses
demonstrated that there was no significant interaction between CSF Aβ1–42 levels and HTN
on WM changes. Further, the main effect of CSF Aβ1–42 and HTN were both significant
when assessed simultaneously, indicating that these measures constitute independent
predictors of WM changes. Several studies suggest that Aβ amyloidosis and HTN are
independent predictors of cognitive outcomes,[45, 46] but this is the first evidence that CSF
Aβ1–42 levels and HTN are independently associated with WM alterations in older adults.
These findings suggest that WM alterations could be viewed as the sum of effects from both
AD and CVD pathology, rather than thought of as either AD or CVD modifying the effect of
the other on WMH burden. This has important implications for therapeutic interventions,
since treating one pathology will only address WM alteration from that disease mechanism
but may have no significant impact on WM changes related to the other condition.

Author Manuscript

After identifying statistically independent relationships of CSF Aβ1–42 levels and HTN with
WM alteration, we sought to determine if this independence was due to spatially distinct
patterns of WM alteration associated with each pathology. We found minimal overlap
between areas of WM alterations associated with CSF Aβ1–42 and HTN; 95% of HTNassociated WMH and 90% of Aβ-associated WMH were unique. Consistent with previous
studies in familial AD, CSF Aβ1–42 was primarily associated with WM alteration in
posterior regions.[11, 12, 43] Although much of the evidence for the relationship between
Aβ1–42 and posterior WM alteration comes from studies of dominantly-inherited AD, the
present study provides support for a similar relationship in sporadic late-onset AD. In
contrast to Aβ1–42-associated WM alterations, HTN-associated WM change was primarily
observed in deep WM. Many of these areas are near watershed regions between the middle
cerebral artery and posterior cerebral artery distributions. These findings are consistent with
previous studies that found CVD risk is associated with greater WM alteration in the
watershed regions and deep WM.[30, 31]

Author Manuscript

An important possibility that must be considered is that the association between the Aβ1–42
and WM alterations in these posterior regions is mediated by cerebral amyloid angiopathy
(CAA), which has a predilection for parietal-occipital cortex. [47] In our study, we found a
relationship between CSF Aβ1–42 and CMBs in the parietal lobe, which is consistent with
extensive previous work. [48, 49] However, regression analyses demonstrated that these
amyloid-associated CMBs did not account for the significant relationship between amyloid
and WMHs. These results suggest that CAA is likely one of multiple mechanisms that
contribute to WM alterations associated with increasing amyloid in the brain.
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There are several limitations to the present study. The cross-sectional design allowed for
measurement of correlations among HTN, CSF Aβ1–42 levels and WMH/FA in NAWM, but
we did not assess the temporal sequence of these changes, precluding causal inferences. In
addition, the sample size may have led to insufficient power to detect small effects. Further,
cardiovascular risk measures were assessed using dichotomous variables (either present or
absent) and did not account for medication control or adherence, disease duration, and/or
severity. This may mask potential relationships that exist between these cardiovascular risk
measures and WM alterations. Additionally, our sample included only those without
dementia. It is unclear whether these relationships are present in individuals with severe
disease(s). Also, the present study did not examine relationships with cognition. Despite
independent effects on WM, CVD risk and AD pathology may have a different relationship
with cognition as demonstrated by a recent study reporting synergistic effects of CVD risk
and AD pathology on cognitive decline. [26] Finally, amyloid PET scans were not collected
as part of this study. Previous work has demonstrated spatial overlap between CAA and PET
amyloid binding. [51, 52] Therefore, future studies should seek to include PET imaging to
examine whether these areas of WM alteration found in the present study share overlap with
these same regions of increased amyloid-PET binding in CAA.

Author Manuscript

In conclusion, the present study demonstrates that the effects of HTN and CSF Aβ1–42 levels
on WM alteration may be additive rather than synergistic, with each associated with distinct
spatial distributions of WM alteration. Considering such spatial distributions may improve
diagnostic accuracy and optimal development of treatment paradigms that address CVD and
AD, either separately or in combination. It is unclear whether the underlying
pathophysiology and injurious mechanisms of these alterations are the same in the different
brain regions. Further studies are needed to explore whether these distinct spatial patterns of
WM alteration are associated with different cognitive processes and/or clinical outcomes.
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Figure 1. Distinct spatial distribution of white matter hyperintensities related to hypertension
and CSF amyloid β1–42 levels.
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The spatial distribution of white matter hyperintensities (WMH) related to hypertension
(HTN) (red) and Cerebrospinal fluid amyloid beta 1–42 levels (Aβ1–42) (green) shows
primarily distinct distributions with minimal overlapping areas (blue). WMH associated with
HTN occur primarily in deep cortical white matter and along the body of the lateral
ventricles. WMH associated with Aβ1–42 occur primarily near the ventricular horns and the
posterior corona radiata. Areas of WMH are displayed on the FMRIB58 FA 1mm3 brain.
Contiguous 1mm slices are shown starting from MNI z = 0 at the top left and MNI z = 48 at
the bottom right. All images are shown in radiological orientation (anatomical right is on the
left side of the image).
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Table 1.

Author Manuscript

Demographics, clinical, imaging and laboratory characteristics of the study cohort.
Variables

CN (N=26)

MCI (N=36)

Total (N=62)

Differences CN vs. MCI (p-value)

Age mean ± sd

76.81 ± 6.14

73.47 ± 7.98

74.87 ± 7.40

0.080

Male sex n (%)

9 (34.6)

19 (52.8)

28 (45.2)

0.156

Education mean ± sd

17.08 ± 2.18

16.83 ± 3.67

16.94 ± 3.12

0.764

mFRS mean ± sd

17.58 ± 2.8

16.56 ± 3.1

17 ± 3

0.189

7 (26.9)

27 (75.0)

34 (54.8)

0.001‡

SBP mean ± sd

135.77 ± 10.77

138.47 ± 16.47

137.34 ± 14.32

0.468

DBP mean ± sd

74.19 ± 9.70

73.89 ± 11.42

74.02 ± 10.65

0.913

Hyperlipidemia n (%)

2 (7.7)

25 (73.5)

27 (43.5)

0.000‡

Diabetes n (%)

4 (15.4)

10 (27.8)

14 (22.6)

0.247

Hypertension n (%)

Author Manuscript

Smoking n (%)

2 (7.7)

1 (2.7)

3 (4.8)

0.567

NAWM-FA mean ± sd

0.59 ± 0.41

0.59 ± 0.55

0.59 ± 0.05

0.987

Aβ1–42 mean ± sd

320 ± 93.14

251.03 ± 90.82

279.95 ± 97.29

0.005¥

WMH volume cc mean ± sd

8.22 ± 9.98

13.30 ± 20.03

11.17 ± 16.65

0.238

CN = cognitively normal; MCI = mild cognitive impairment; mFRS = modified Framingham stroke risk score; SBP = systolic blood pressure; DBP
= diastolic blood pressure; HLD = hyperlipidemia; NAWM-FA = fractional anisotropy values of the normally appearing white matter; Aβ1–42 =
Cerebrospinal fluid amyloid beta 1–42 levels; WMH = white matter hyperintensities.

‡

Pearson Chi-square

¥

T test (2 sided)
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Table 2.

Author Manuscript

Partial Correlation of hypertension, CSF amyloid β1–42levels and imaging measures of micro and
macrostructural white matter alteration in study subjects.
HTN

Aβ1–42

HLD

DM

mFRS

WMH volume

NAWM-FA

HTN

--

−0.01

0.308*

0.207

0.026

0.298*

−0.233

Aβ1–42

--

--

0.036

0.188

−0.057

−0.300*

0.400**

HLD

--

--

--

0.083

0.078

0.056

−0.036

DM

--

--

--

--

−0.001

−0.100

0.019

mFRS

--

--

--

--

--

−0.041

−0.007

WMH volume

--

--

--

--

--

--

−0.481‡

Values are partial correlation coefficients adjusted for age, gender and cognitive status; HTN = hypertension; Aβ1–42 = Cerebrospinal fluid

Author Manuscript

amyloid beta 1–42 levels; HLD = hyperlipidemia; DM = diabetes mellitus; mFRS = modified Framingham stroke risk score; WMH = white matter
hyperintensity; NAWM-FA = fractional anisotropy values of the normally appearing white matter.

*

P ≤ 0.05

**
P ≤ 0.01
‡

P ≤ 0.001
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Table 3.

Author Manuscript

Linear regression models to examine the effects of hypertension and Cerebrospinal fluid amyloid beta 1–42
levels on white matter hyperintensity burden.
Aβ1–42

HTN

Aβ1–42 × HTN

a

B = −0.28 (.026)

B = 0.30 (.017)

B = 0.03 (.829)

a

B = −0.28 (.016)

B = 0.30 (.016)

--

b

B = −0.28 (.024)

B = 0.32 (.012)

B = 0.04 (.728)

b

B = −0.29 (.013)

B = 0.32 (.011)

--

Model 1 (F5,56 = 7.7, R2 = 0.409, p < 0.001)
Model 2 (F6,55 = 6.3, R2 = 0.408, p < 0.001)
Model 3 (F7,54 = 5.8, R2 = 0.432, p < 0.001)
Model 4 (F6,55 = 6.9, R2 = 0.431, p < 0.001)

Linear regression models using white matter hyperintensity (WMH) volume as the dependent variable. Values shown are standardized βcoefficients with p-values in parentheses. Predictors of interest were CSF levels of Aβ1–42, HTN, and Aβ1–42 × HTN interaction (Models 1, 3).
The analyses were repeated without the non-significant interaction term (Models 2, 4).
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a

Covariates included in models 1 & 2 were age, sex, and cognitive status.

b

Covariates included in models 3 & 4 were age, sex, cognitive status, and mFRS.
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Table 4.

Author Manuscript

Linear regression models to examine the effects of hypertension and Cerebrospinal fluid amyloid beta 1–42
levels on white matter microstructural alterations.
Aβ1–42

HTN

Aβ1–42 × HTN

a

B = 0.016 (.007)

B = −0.01 (.065)

B = −0.01 (.143)

a

B = 0.018 (.001)

B = −0.011 (.067)

--

b

B = 0.016 (.007)

B = −.0011 (.063)

B = −0.008 (.138)

b

B = 0.018 (.001)

B = −0.011 (.067)

--

Model 1 (F6,55 = 7.0, R2 = 0.432, p < 0.001)
Model 2 (F5,56 = 7.8, R2 = 0.409, p < 0.001)
Model 3 (F7,54 = 5.9, R2 = 0.434, p < 0.001)
Model 4 (F6,55 = 6.4, R2 = 0.410, p < 0.001)

Linear regression models using the fractional anisotropy values of the normally appearing white matter (NAWM-FA) as the dependent variable.
Values shown are standardized β-coefficients with p-values in parentheses. Predictors of interest were CSF levels of Aβ1–42, HTN, and Aβ1–42 ×
HTN interaction (Models 1, 3). The analyses were repeated without the non-significant interaction term (Models 2, 4).
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a

Covariates included in models 1 & 2 were age, gender, and cognitive status.

b

Covariates included in models 3 & 4 were age, gender, cognitive status, and mFRS.
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